Cholangiocarcinoma: a guide for the nonspecialist

Alsaleh, Munirah; Leftley, Zoe; Barbera, Thomas; Sithithaworn, Paiboon; Khuntikeo, Narong; Loilome, Watcharin; Yongvanit, Puangrat; Cox, I. Jane; Chamodol, Nittaya; Syms, R.R.A.; Andrews, Ross H.; Taylor-Robinson, Simon D

doi:10.2147/ijgm.s186854

Cited by 76 publications

(69 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cholangiocarcinoma (CCA) is the most common biliary tract primary malignancy and the second most common liver malignancy following HCC, worldwide [97]. Asia has more CCA patients than other regions, but the prevalence of CCA is increasing in North America and Europe [98]. CCA tumors are categorized into intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) subtypes [99].…”

Section: Mir-144 In Cholangiocarcinomamentioning

confidence: 99%

MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers

Kooshkaki

Rezaei

Rahmati

et al. 2020

IJMS

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small and non-coding RNAs that display aberrant expression in the tissue and plasma of cancer patients when tested in comparison to healthy individuals. In past decades, research data proposed that miRNAs could be diagnostic and prognostic biomarkers in cancer patients. It has been confirmed that miRNAs can act either as oncogenes by silencing tumor inhibitors or as tumor suppressors by targeting oncoproteins. MiR-144s are located in the chromosomal region 17q11.2, which is subject to significant damage in many types of cancers. In this review, we assess the involvement of miR-144s in several cancer types by illustrating the possible target genes that are related to each cancer, and we also briefly describe the clinical applications of miR-144s as a diagnostic and prognostic tool in cancers.Int. J. Mol. Sci. 2020, 21, 2578 2 of 23 of a mRNA molecule [3]. MiRNAs indicate a new perspective in the study of cancers. More than 50% of miRNA genes were discovered to be located within the genomic regions that are involved in cancers, suggesting their role in human cancer pathogenesis. In pathological conditions, MiRNAs can negatively regulate gene expression and they are associated with tumor growth, apoptosis, invasion, and metastasis. In the past, several studies have indicated the ability of miRNAs in the inhibition of tumors as a critical option for the improvement of cancer therapy [4,5]. Tumor activator miRNAs, called oncomiRs, are overexpressed in various cancers. On the contrary, suppressive tumor miRNAs are underexpressed [6][7][8]. Among several miRNAs assessed, miR-144s seem to have a role in several cancers. These miRNAs are located in the chromosomal region 17q11.2, being significantly destroyed in many types of cancers. The predicted stem-loop structure of miR-144s recognized by the miRBase (http://mirbase.org/) is shown in Figure 1A. The miR-144 hairpin gives rise to the "guide strand" miR-144-5p and the sister "passenger" strand miR-144-3p ( Figure 1B).

show abstract

Section: Mir-144 In Cholangiocarcinomamentioning

confidence: 99%

MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers

Kooshkaki

Rezaei

Rahmati

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…CCA is a malignancy of the cholangiocytes in the biliary tree . It accounts for 10%–20% of all hepatic cancers, and PSC is the most common risk factor . CCA often goes undetected until the later stages of life, most often discovered between 70 and 79 years of age, as most signs and symptoms are absent .…”

Section: Overview Of Different Liver Diseasesmentioning

confidence: 99%

“…CCA often goes undetected until the later stages of life, most often discovered between 70 and 79 years of age, as most signs and symptoms are absent . If the CCA tumor is large enough to block bile flow, symptoms such as jaundice, pruritus, and/or pale stools may be seen . Those with CCA will also have the same micronutrient concerns as those with PBC and PSC.…”

Section: Overview Of Different Liver Diseasesmentioning

confidence: 99%

Micronutrients in Liver Disease: Roles, Risk Factors for Deficiency, and Recommendations for Supplementation

et al. 2019

View full text Add to dashboard Cite

Micronutrients are essential components of the diet and are required to maintain fundamental bodily functions. Liver disease has a profound effect on nutrient intake, metabolism of nutrients, and nutrition status, often resulting in some degree of malnutrition, including micronutrient deficiency. Vitamin and mineral deficiencies can impair metabolic processes at the cellular and biochemical level even before clinical and physical alterations are seen. It is essential that micronutrient status is evaluated as part of a comprehensive nutrition assessment for all patients with chronic or advanced liver disease. Early intervention to correct suspected or confirmed deficiencies may minimize symptoms and improve clinical outcomes and quality of life. In this narrative review, different types of liver disease and associated micronutrient abnormalities are outlined, and methods of micronutrient assessment and supplementation are discussed. (Nutr Clin Pract. 2020;35:50-62)

show abstract

“…1,4 The typical clinical symptom of ECC is features of biliary obstruction including jaundice, pale stool, dark urine and pruritus. [5][6][7] The diagnosis of ECC is based on clinical manifestation, blood test, imaging, and histology and cytology. 5 Imaging is the main diagnostic method for ECC, including ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), endoscopic retrograde cholangiopancreatography (ERCP).…”

Section: Introductionmentioning

confidence: 99%

“…5 Imaging is the main diagnostic method for ECC, including ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), endoscopic retrograde cholangiopancreatography (ERCP). 6 Current treatment strategies for ECC include surgery, systemic chemotherapy and targeted radiation. 8 Surgical resection is the only curative treatment approach for ECC.…”

Section: Introductionmentioning

confidence: 99%

<p>Prognostic and Clinicopathological Significance of EphB3 and Dysadherin Expression in Extrahepatic Cholangiocarcinoma</p>

Wu¹,

Liu²,

Xiong³

et al. 2020

CMAR

View full text Add to dashboard Cite

Aim: EphB3 and dysadherin are involved in tumorigenesis and progression of many neoplasms. However, the roles of EphB3 and dysadherin in extrahepatic cholangiocarcinoma (ECC) remain to be revealed. In this study, we aimed to evaluate the expression of EphB3 and dysadherin, and investigate their clinicopathological significance in ECC. Methods: We examined EphB3 and dysadherin expression in 100 ECC, 30 peritumoral tissues, 10 adenoma and 15 normal biliary tract tissues using EnVision immunohistochemistry. The relationship between EphB3 or dysadherin expression and clinicopathological features was evaluated using the χ 2 test or Fisher's exact test. The overall survival of ECC patients was analyzed using Kaplan-Meier univariate survival analysis and Log rank tests. Results: We found that EphB3 expression was significantly down-regulated and dysadherin expression was significantly up-regulated in ECC tissues compared with normal tissues (P < 0.01). EphB3 expression was negatively correlated with dysadherin expression in ECC (P < 0.01). The positive rate of EphB3 expression and negative rate of dysadherin expression was significantly higher in patients with well-differentiated type, no lymph node metastasis, no surrounding tissues and organs invasion, early TNM stages (I + II) and radical resection (P < 0.01). The survival of ECC patients with positive EphB3 or negative dysadherin expression was significantly longer than patients with negative EphB3 or positive dysadherin expression (P < 0.01). Cox multivariate analysis demonstrated that negative EphB3 or positive dysadherin expression were independent poor prognostic factors in ECC patients. The ROC curves suggested that EphB3 and dysadherin combined diagnostic efficacy (AUC=0.688, 95%CI: 0.603-0.772) was significantly higher EphB3 diagnostic efficacy (AUC=0.654, 95%CI: 0.564-0.743) or dysadherin diagnostic efficacy (AUC=0.648, 95%CI: 0.558-0.737) alone. Conclusion: EphB3 and dysadherin are involved in the carcinogenesis and progression of ECC, and ECC patients with negative EphB3 or positive dysadherin expression have a poor prognosis.

show abstract

Cholangiocarcinoma: a guide for the nonspecialist

Cited by 76 publications

References 50 publications

MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers

MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers

Micronutrients in Liver Disease: Roles, Risk Factors for Deficiency, and Recommendations for Supplementation

<p>Prognostic and Clinicopathological Significance of EphB3 and Dysadherin Expression in Extrahepatic Cholangiocarcinoma</p>

Contact Info

Product

Resources

About